{"id":8843,"date":"2020-04-07T17:57:19","date_gmt":"2020-04-07T12:27:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8843"},"modified":"2024-09-17T16:25:19","modified_gmt":"2024-09-17T10:55:19","slug":"recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech","title":{"rendered":"Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration;  INO-4800 DNA COVID-19 Vaccine;  Pfizer Commits $ 40M for COVID-19"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a43e63be0dd0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a43e63be0dd0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech\/#Immunomedics_discontinues_its_trial_early_%E2%80%93_hopes_for_accelerated_approval_of_Sacituzumab_govitecan_for_mTNBC\" >Immunomedics discontinues its trial early \u2013 hopes for accelerated approval of Sacituzumab govitecan for mTNBC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech\/#GSK_Vir_Biotechnology_collaborates_to_advance_therapy_development_for_COVID-19\" >GSK, Vir Biotechnology collaborates to advance therapy development for COVID-19<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech\/#FDA_accepts_IND_application_for_Inovios_INO-4800_%E2%80%93_DNA_vaccine_against_SARS_CoV-2\" >FDA accepts IND application for Inovio\u2019s INO-4800 \u2013 DNA vaccine against SARS CoV-2<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech\/#Pfizer_and_The_Pfizer_Foundation_commits_USD_40_Million_fosters_the_efforts_to_combat_COVID_crisis\" >Pfizer and The Pfizer Foundation commits USD 40 Million, fosters the efforts to combat COVID crisis&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-immunomedics-discontinues-its-trial-early-hopes-for-accelerated-approval-of-sacituzumab-govitecan-for-mtnbc\"><span class=\"ez-toc-section\" id=\"Immunomedics_discontinues_its_trial_early_%E2%80%93_hopes_for_accelerated_approval_of_Sacituzumab_govitecan_for_mTNBC\"><\/span><strong>Immunomedics discontinues its trial early \u2013 hopes for accelerated approval of Sacituzumab govitecan for mTNBC<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Immunomedics<\/strong>&#8211; a New Jersey-based pharmaceutical company has announced to freeze its Phase III confirmatory ASCENT clinical trial of <strong>sacituzumab govitecan<\/strong> aimed at treating <strong><em><a href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-market\">metastatic triple-negative breast cancer (mTNBC)<\/a>.<\/em><\/strong><\/p>\n\n\n\n<p><em>An independent Data Safety Monitoring Committee (DSMC) recommended they stop the trial because of \u201ccompelling evidence of efficacy.\u201d<\/em><\/p>\n\n\n\n<p>The company, focused on developing antibody-drug conjugates for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-negative-breast-cancer-market\">cancer<\/a>, is waiting on the results of its resubmission of accelerated approval of the drug under review by the FDA. The company is hopeful of getting the recommendation upon a successful meeting of multiple endpoints in the ASCENT study.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gsk-vir-biotechnology-collaborates-to-advance-therapy-development-for-covid-19\"><span class=\"ez-toc-section\" id=\"GSK_Vir_Biotechnology_collaborates_to_advance_therapy_development_for_COVID-19\"><\/span><strong>GSK, Vir Biotechnology collaborates to advance therapy development for COVID-19<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>GlaxoSmithKline has announced to partner with Vir Biotechnology to improve research and development and develop a cure for the treatment of <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\">COVID-19<\/a>.<\/p>\n\n\n\n<p>The collaboration has planned to use Vir\u2019s proprietary monoclonal antibody platform technology to identify new anti-viral antibodies and accelerate the development of existing ones to be used as a therapeutic option against <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus-2019-ncov-is-now-covid-19\">COVID-19<\/a>. However, the primary focus would be on the development of VIR-7831 and VIR-7832 \u2013 which have shown a high affinity for SARS-CoV-2 SPIKE PROTEIN.\u00a0<\/p>\n\n\n\n<p>Under terms of the deal, GSK has made a USD 250 million equity investment into Vir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-accepts-ind-application-for-inovio-s-ino-4800-dna-vaccine-against-sars-cov-2\"><span class=\"ez-toc-section\" id=\"FDA_accepts_IND_application_for_Inovios_INO-4800_%E2%80%93_DNA_vaccine_against_SARS_CoV-2\"><\/span><strong>FDA accepts IND application for Inovio\u2019s INO-4800 \u2013 DNA vaccine against SARS CoV-2<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Inovio Pharmaceuticals has received Investigational New Drug (IND) for its INO-4800 by the FDA, facilitating its way ahead to initiate Phase I clinical trials.&nbsp;<\/p>\n\n\n\n<p>The company would initiate Phase 1 clinical testing of INO-4800 in healthy volunteers beginning today. The trial would recruit up to 40 healthy adults in Philadelphia and Kansas. Preclinical data shows hopeful immune response results across multiple animal models. Additional preclinical trials, including challenge studies, will continue in parallel with the Phase 1 clinical trial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pfizer-and-the-pfizer-foundation-commits-usd-40-million-fosters-the-efforts-to-combat-covid-crisis\"><span class=\"ez-toc-section\" id=\"Pfizer_and_The_Pfizer_Foundation_commits_USD_40_Million_fosters_the_efforts_to_combat_COVID_crisis\"><\/span><strong>Pfizer and The Pfizer Foundation commits USD 40 Million, fosters the efforts to combat COVID crisis&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer and The Pfizer Foundation has announced to donate USD 40 million in medical and charitable cash grants to encourage the efforts to tackle <a href=\"https:\/\/www.delveinsight.com\/blog\/questions-and-answers-on-coronavirus-covid-19\">COVID-19<\/a> in the US and all over the world.\u00a0<\/p>\n\n\n\n<p>The company plans on expanding product assessment and mobilize its colleagues to Combat <a href=\"https:\/\/www.delveinsight.com\/blog\/realm-of-pandemics\">COVID-19 Pandemic<\/a>. The donation would be used to address the urgent needs of its partners working to prevent the transmission of the virus.\u00a0<\/p>\n\n\n\n<p>Pfizer is also evolving its US Patient Assistance Program and donating additional critical medicines and vaccines. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immunomedics discontinues its trial early \u2013 hopes for accelerated approval of Sacituzumab govitecan for mTNBC Immunomedics&#8211; a New Jersey-based pharmaceutical company has announced to freeze its Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan aimed at treating metastatic triple-negative breast cancer (mTNBC). An independent Data Safety Monitoring Committee (DSMC) recommended they stop the trial [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8855,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[16659,903,2116,3245,420,460,6790,5789,18215],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-8843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-covid","tag-gsk","tag-immunomedics","tag-inovio-pharmaceuticals","tag-news","tag-pfizer","tag-recent-news","tag-recent-pharma-news","tag-vir-biotechnology","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Immunomedics, GSK, Vir Biotechnology<\/title>\n<meta name=\"description\" content=\"FDA accepts IND application for Inovio\u2019s INO-4800. Inovio Pharma has received Investigational New Drug for its INO-4800.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Immunomedics, GSK, Vir Biotechnology\" \/>\n<meta property=\"og:description\" content=\"FDA accepts IND application for Inovio\u2019s INO-4800. Inovio Pharma has received Investigational New Drug for its INO-4800.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-07T12:27:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T10:55:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/07181703\/Blog-Images.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Immunomedics, GSK, Vir Biotechnology","description":"FDA accepts IND application for Inovio\u2019s INO-4800. Inovio Pharma has received Investigational New Drug for its INO-4800.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Immunomedics, GSK, Vir Biotechnology","og_description":"FDA accepts IND application for Inovio\u2019s INO-4800. Inovio Pharma has received Investigational New Drug for its INO-4800.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-04-07T12:27:19+00:00","article_modified_time":"2024-09-17T10:55:19+00:00","og_image":[{"width":750,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/07181703\/Blog-Images.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech","name":"Pharma News | Immunomedics, GSK, Vir Biotechnology","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/07181703\/Blog-Images.jpg","datePublished":"2020-04-07T12:27:19+00:00","dateModified":"2024-09-17T10:55:19+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"FDA accepts IND application for Inovio\u2019s INO-4800. Inovio Pharma has received Investigational New Drug for its INO-4800.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-inovio-immunomedics-gsk-vir-biotech#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/07181703\/Blog-Images.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/07181703\/Blog-Images.jpg","width":750,"height":482,"caption":"pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/07181703\/Blog-Images-300x193.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Immunomedics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Inovio Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vir Biotechnology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">COVID<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">Immunomedics<\/span>","<span class=\"advgb-post-tax-term\">Inovio Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">recent news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Vir Biotechnology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 7, 2020","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Apr 7, 2020 5:57 pm","modified":"Updated on Sep 17, 2024 4:25 pm"},"featured_img_caption":"pharma news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8843"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8843\/revisions"}],"predecessor-version":[{"id":28003,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8843\/revisions\/28003"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8855"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8843"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8843"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}